Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | Vertex Pharmaceuticals Newsroom (vrtx.com)

31 patients with severe Sickle Cell Disease characterized by recurrent vaso-occlusive crises (VOCs) (mean of 3.9 VOCs per year over the prior two years) were free of excruciating pain episodes after an exa-cel infusion through duration of follow-up, with follow-up ranging from 2.0 to 32.3 months.